Twist Bioscience: Overview of First Fiscal Quarter Results
Twist Bioscience Reports First Quarter Financial Results
Twist Bioscience Corp., headquartered in South San Francisco, announced a net loss of $30.5 million for its fiscal first quarter.
The company, which specializes in producing synthetic DNA for the biotech sector, reported a quarterly loss of 50 cents per share.
During this period, Twist Bioscience generated $103.7 million in revenue.
Looking ahead to the quarter ending in March, the company anticipates revenue between $107 million and $108 million.
For the full fiscal year, projected revenue is expected to fall within the range of $435 million to $440 million.
This article was produced by Automated Insights using information from Zacks Investment Research.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Oil: Risk premium builds on Hormuz threat – MUFG
Ethereum price prediction: could it remain below $2k as whales cut holdings over 90 days?

Kyber Network up 23% while majors lag, cross‑chain DEX upgrades fuel bid
Money and Lending - January 2026
